Analysis of primary cells from a BCR-ABL mutation-independent imatinib resistant patient by mass cytometry suggested that the synergy may be due to downregulation of the MAPK pathway by avasimibe, which sensitized the CML cells to imatinib treatment. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.